Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Jiang, LiLi ^a,b   Siu, Michelle K Y ^a   Wong, Oscar G W ^a   Tam, Kar F ^a   Lam, Eric W F ^c   Ngan, Hextan Y S ^a   Le, Xiao Feng ^d   Wong, Esther S Y ^a   Chan, Hoi Y ^a   Cheung, Annie N Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SICHUAN UNIVERSITY   (China)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FACTOR THAT BINDS TO THE INDUCER OF SHORT TRANSCRIPTS OF HUMAN IMMUNODEFICIENCY VIRUS 1; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ZBTB7A PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYSTADENOMA; DISEASE FREE SURVIVAL; DNA FLANKING REGION; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PROTO ONCOGENE; CELL LINE; CELL MOTION; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROTEIN BINDING; TUMOR CELL LINE; WESTERN BLOTTING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AGED; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 14; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN BINDING; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 78650278812     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-318     Document Type: Article

References (43)

1. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001, 22:255-288. 10.1210/er.22.2.255, 11294827.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
3. Chernov AV, Sounni NE, Remacle AG, Strongin AY. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem 2009, 284:12727-12734. 10.1074/jbc.M900273200, 2676002, 19286653.
4. Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D, Foidart JM. Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 2004, 57:577-584. 10.1136/jcp.2003.014472, 1770325, 15166260.
5. Ruangpanit N, Price JT, Holmbeck K, Birkedal-Hansen H, Guenzler V, Huang X, Chan D, Bateman JF, Thompson EW. MT1-MMP-dependent and -independent regulation of gelatinase A activation in long-term, ascorbate-treated fibroblast cultures: regulation by fibrillar collagen. Exp Cell Res 2002, 272:109-118. 10.1006/excr.2001.5403, 11777335.
6. Strongin AY. Mislocalization and unconventional functions of cellular MMPs in cancer. Cancer Metastasis Rev 2006, 25:87-98. 10.1007/s10555-006-7892-y, 16680575.
7. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995, 270:5331-5338. 10.1074/jbc.270.10.5331, 7890645.
8. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008, 40:1362-1378. 10.1016/j.biocel.2007.12.006, 18258475.
9. Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG, Stack MS. Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res 2009, 69:7121-7129. 10.1158/0008-5472.CAN-08-4151, 2737080, 19706774.
10. Barbolina MV, Adley BP, Ariztia EV, Liu Y, Stack MS. Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J Biol Chem 2007, 282:4924-4931. 10.1074/jbc.M608428200, 17158885.
11. Afzal S, Lalani EN, Poulsom R, Stubbs A, Rowlinson G, Sato H, Seiki M, Stamp GW. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 1998, 29:155-165. 10.1016/S0046-8177(98)90226-X, 9490275.
12. Adley BP, Gleason KJ, Yang XJ, Stack MS. Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol Oncol 2009, 112:319-324. 10.1016/j.ygyno.2008.09.025, 2663392, 18976802.
13. Munkert A, Helmchen U, Kemper MJ, Bubenheim M, Stahl RA, Harendza S. Characterization of the transcriptional regulation of the human MT1-MMP gene and association of risk reduction for focal-segmental glomerulosclerosis with two functional promoter SNPs. Nephrol Dial Transplant 2009, 24:735-742. 10.1093/ndt/gfn576, 18927121.
14. Pessler F, Pendergrast PS, Hernandez N. Purification and characterization of FBI-1, a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts. Mol Cell Biol 1997, 17:3786-3798. 232230, 9199312.
15. Lee DK, Kang JE, Park HJ, Kim MH, Yim TH, Kim JM, Heo MK, Kim KY, Kwon HJ, Hur MW. FBI-1 enhances transcription of the nuclear factor-kappaB (NF-kappaB)-responsive E-selectin gene by nuclear localization of the p65 subunit of NF-kappaB. J Biol Chem 2005, 280:27783-27791. 10.1074/jbc.M504909200, 15917220.
16. Laudes M, Christodoulides C, Sewter C, Rochford JJ, Considine RV, Sethi JK, Vidal-Puig A, O'Rahilly S. Role of the POZ zinc finger transcription factor FBI-1 in human and murine adipogenesis. J Biol Chem 2004, 279:11711-11718. 10.1074/jbc.M310240200, 14701838.
17. Maeda T, Merghoub T, Hobbs RM, Dong L, Maeda M, Zakrzewski J, van den Brink MR, Zelent A, Shigematsu H, Akashi K, et al. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science 2007, 316:860-866. 10.1126/science.1140881, 2978506, 17495164.
18. Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 2005, 433:278-285. 10.1038/nature03203, 15662416.
19. Schubot FD, Tropea JE, Waugh DS. Structure of the POZ domain of human LRF, a master regulator of oncogenesis. Biochem Biophys Res Commun 2006, 351:1-6. 10.1016/j.bbrc.2006.09.167, 17052694.
20. Jeon BN, Yoo JY, Choi WI, Lee CE, Yoon HG, Hur MW. Proto-oncogene FBI-1 (Pokemon/ZBTB7A) represses transcription of the tumor suppressor Rb gene via binding competition with Sp1 and recruitment of co-repressors. J Biol Chem 2008, 283:33199-33210. 10.1074/jbc.M802935200, 2662252, 18801742.
21. Maeda T, Ito K, Merghoub T, Poliseno L, Hobbs RM, Wang G, Dong L, Maeda M, Dore LC, Zelent A, et al. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev Cell 2009, 17:527-540. 10.1016/j.devcel.2009.09.005, 19853566.
22. Apostolopoulou K, Pateras IS, Evangelou K, Tsantoulis PK, Liontos M, Kittas C, Tiniakos DG, Kotsinas A, Cordon-Cardo C, Gorgoulis VG. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer. J Pathol 2007, 213:294-302. 10.1002/path.2222, 17907153.
23. Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T. The UMD TP53 database and website: update and revisions. Hum Mutat 2006, 27:14-20. 10.1002/humu.20269, 16278824.
24. Lohi J, Lehti K, Valtanen H, Parks WC, Keski-Oja J. Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene 2000, 242:75-86. 10.1016/S0378-1119(99)00549-1, 10721699.
25. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 2006, 33:S3-11. 10.1053/j.seminoncol.2006.03.011, 16716797.
26. Gozzetti A, Davis EM, Espinosa R, Fernald AA, Anastasi J, Le Beau MM. Identification of novel cryptic translocations involving IGH in B-cell non-Hodgkin's lymphomas. Cancer Res 2002, 62:5523-5527.
27. Maeda T, Hobbs RM, Pandolfi PP. The transcription factor Pokemon: a new key player in cancer pathogenesis. Cancer Res 2005, 65:8575-8578. 10.1158/0008-5472.CAN-05-1055, 16204018.
28. Choi WI, Jeon BN, Park H, Yoo JY, Kim YS, Koh DI, Kim MH, Kim YR, Lee CE, Kim KS, et al. Proto-oncogene FBI-1 (Pokemon) and SREBP-1 synergistically activate transcription of fatty-acid synthase gene (FASN). J Biol Chem 2008, 283:29341-29354. 10.1074/jbc.M802477200, 2662021, 18682402.
29. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005, 5:355-366. 10.1038/nrc1611, 15864277.
30. Gingras D, Beliveau R. Emerging concepts in the regulation of membrane-type 1 matrix metalloproteinase activity. Biochim Biophys Acta 2010, 1803:142-150. 10.1016/j.bbamcr.2009.04.011, 19409422.
31. Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci 2009, 122:3015-3024. 10.1242/jcs.034561, 19692588.
32. Sroka IC, Nagle RB, Bowden GT. Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia 2007, 9:406-417. 10.1593/neo.07193, 1877982, 17534446.
33. Haas TL, Stitelman D, Davis SJ, Apte SS, Madri JA. Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem 1999, 274:22679-22685. 10.1074/jbc.274.32.22679, 10428849.
34. Choi WI, Jeon BN, Yun CO, Kim PH, Kim SE, Choi KY, Kim SH, Hur MW. Proto-oncogene FBI-1 represses transcription of p21CIP1 by inhibition of transcription activation by p53 and Sp1. J Biol Chem 2009, 284:12633-12644. 10.1074/jbc.M809794200, 2675992, 19244234.
35. Au CW, Siu MK, Liao X, Wong ES, Ngan HY, Tam KF, Chan DC, Chan QK, Cheung AN. Tyrosine kinase B receptor and BDNF expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcome. Cancer Lett 2009, 281:151-161. 10.1016/j.canlet.2009.02.025, 19307055.
36. Siu MK, Wong ES, Chan HY, Ngan HY, Chan KY, Cheung AN. Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome. Am J Pathol 2008, 173:1165-1172. 10.2353/ajpath.2008.080288, 2543083, 18772339.
37. Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, Ngan HY, Cheung AN. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis 2009, 30:131-140. 10.1093/carcin/bgn230, 19028702.
38. Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, et al. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia 12:161-172. 2814354, 20126474.
39. Mori M, Mimori K, Shiraishi T, Fujie T, Baba K, Kusumoto H, Haraguchi M, Ueo H, Akiyoshi T. Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 1997, 74:316-321. 10.1002/(SICI)1097-0215(19970620)74:3<316::AID-IJC14>3.0.CO;2-9, 9221811.
40. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montano J, Chang H, Rozmus J, Russell JA, Edwards DR, Turner AR. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood 1999, 93:3379-3390.
41. Zhou HY, Wan KF, Ip CK, Wong CK, Mak NK, Lo KW, Wong AS. Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. FEBS Lett 2008, 582:3415-3422. 10.1016/j.febslet.2008.09.004, 18789327.
42. Woenckhaus J, Steger K, Sturm K, Munstedt K, Franke FE, Fenic I. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch 2007, 450:387-395. 10.1007/s00428-006-0358-3, 17377809.
43. Petrella BL, Lohi J, Brinckerhoff CE. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 2005, 24:1043-1052. 10.1038/sj.onc.1208305, 1847637, 15592504.